AI channel feed – Endpoints News

AI channel feed

Exclusive: Terray raises $120M for its AI ways of designing molecules

8 months ago

How Endpoints covers AI, and a chance to hear from two Nobel winners

8 months ago

Letters to the Editor

AI biotechs Recursion and Exscientia first held deal talks in 2022

9 months ago

Suki nabs $70M Series D to arm doctors with AI tools

9 months ago

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

9 months ago

AI biotech insitro partners with Lilly on metabolic disease drugs

9 months ago

Basecamp raises $60M to travel the globe and fill AI data gaps, signs deal with David Liu

9 months ago

BioNTech opens the hood on its AI ambitions, and they're not just for mRNA

9 months ago

Scoop: Founding CEO leaves Atomwise, casting doubt over a once high-flying AI startup

9 months ago

Exclusive: After discovering antibiotics with AI, a 31-year-old first-time CEO raises $17M to fight aging

9 months ago

Merck, Evaxion expand collaboration with infectious disease vaccine pact

9 months ago

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

9 months ago

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

9 months ago

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

9 months ago

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

9 months ago

Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs

10 months ago

Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

10 months ago

Exclusive: ZipBio launches using generative AI to make compact proteins

10 months ago

With few specifics, Recursion underwhelms with first Phase 2 readout, but ‘plans to advance’ drug

10 months ago

Recursion nears ‘moment of truth’ with first key data, kicking off 18-month flurry of readouts

10 months ago

Exclusive: Noetik raises $40M Series A to advance AI ambitions in cancer — with an unlikely lead investor

10 months ago

In a reality check for the field, AI underwhelms in Leash Bio's binding contest: 'No one did well'

10 months ago

Updated: Recursion to acquire Exscientia to bolster pipeline in one of AI bio’s biggest M&A deals

11 months ago

FDA grapples with its role in AI, and how to guide industry's adoption

11 months ago

First page Previous page 1 2 345 6 7 Next page Last page